Alpha lactalbumin market seen doubling by 2035 on infant nutrition demand

The global alpha lactalbumin market is projected to rise from USD 728.4 million in 2025 to USD 1,512.6 million by 2035, driven by infant formula demand, specialty nutrition, and Asia-Pacific growth. The market is also being shaped by precision fermentation efforts that could broaden supply beyond conventional dairy processing.

Why it matters: - Alpha lactalbumin is becoming a higher-value protein ingredient in infant nutrition, medical nutrition, sports nutrition, and functional foods. - The market’s projected growth points to rising demand for protein fractions that more closely match human milk and support specialized nutrition formats. - Precision fermentation could change how the ingredient is produced, which may affect supply, cost, and consistency over time.

What happened: - The global alpha lactalbumin market was valued at USD 728.4 million in 2025. - The market is projected to reach USD 1,512.6 million by 2035. - The forecast implies a 7.4% compound annual growth rate from 2026 to 2035. - Market Research Future published the assessment covering product type, application, and geography across the 2021–2035 study period. - The report says infant nutrition is the main demand engine, with Asia-Pacific expected to be the fastest-growing region. - The report includes a free sample copy at More information.

The details: - Alpha lactalbumin is the predominant whey protein in human milk and contains essential amino acids, including tryptophan. - Human alpha-lactalbumin is the faster-growing product category because of its biological relevance to human milk. - Human alpha-lactalbumin is being targeted for advanced infant nutrition and precision-fermented dairy alternatives. - Bovine alpha-lactalbumin remains the established commercial base of the market. - Bovine alpha-lactalbumin is recovered from bovine whey through separation and fractionation processes. - Infant formula is the central application segment. - Alpha-lactalbumin supports low-protein formulas, where protein quality matters more as total protein drops. - Dietary supplements are emerging as a growth segment tied to recovery, cognitive wellness, and sleep-related nutrition. - A 2025 randomized crossover study found seven days of pre-sleep alpha-lactalbumin supplementation did not improve habitual sleep or physical performance among athletes with mild-to-moderate sleep difficulties. - Medical and clinical nutrition is another targeted use case, especially for older adults and patients with higher nutritional needs. - Functional foods and beverages remain a broader opportunity, including protein drinks, powders, and bars. - Europe remains a production and innovation hub because of its dairy-processing base and specialty ingredient manufacturers. - North America is an important market for whey fractions, sports nutrition, and specialized formulations. - Latin America and the Middle East & Africa are developing markets where growth depends on nutrition demand, dairy processing, healthcare nutrition, and retail expansion.

Between the lines: - The market is moving beyond conventional whey processing toward higher-value protein fractions. - Manufacturers are competing on purity, yield, cost efficiency, traceability, and formulation performance. - Traditional supply still depends on dairy and whey availability, which makes raw-material access strategically important. - Precision fermentation could reduce dependence on agricultural supply swings if it can achieve competitive yields and purification economics. - Scientific validation remains a hurdle because some potential health applications still rest on early-stage or non-human evidence. - The competitive field remains led by established dairy-ingredient companies with whey access and fractionation capability. - Arla Foods Ingredients holds an estimated 14% to 18% revenue share, followed by Lactalis Ingredients at 10% to 13%, FrieslandCampina at 9% to 12%, and Fonterra at 8% to 11%. - Agropur, Glanbia Nutritionals, Hilmar Ingredients, Carbery Group, and Milk Specialties Global make up another layer of competition. - Recombinant fermentation startups are estimated at 2% to 4% and could reshape the supply structure over the longer term. - In December 2025, Dyadic and BRIG BIO announced a development and commercialization agreement for recombinant bovine alpha-lactalbumin. - The companies said the collaboration is aimed at scalable, animal-free production for early-life, active, healthy-aging, and medical nutrition applications. - In 2026, Dyadic and BRIG BIO initiated scale-up activities under the funded program.

What's next: - Asia-Pacific is expected to add the most incremental demand as infant formula and specialized nutrition categories expand. - Human alpha-lactalbumin and dietary supplements are likely to post faster growth than the mature bovine segment. - Regulatory acceptance, production economics, purity, scalability, and consumer acceptance will determine how quickly human and recombinant forms can scale. - Continued commercialization work in precision fermentation could broaden supply options beyond dairy-derived ingredients. - The market’s next phase will depend on whether manufacturers can prove nutritional performance and keep costs competitive.

The bottom line: - Alpha lactalbumin is shifting from a niche dairy fraction to a strategic nutrition ingredient with room to grow across infant formula, supplements, and clinical nutrition.